UNASSIGNED: 16 Background: Financial @entity137 (FTox) is an important symptom. We hypothesized that FTox can be graded based on statistically significant and clinically meaningful changes in HRQoL. METHODS: FTox was assessed by the COST (COmprehensive Score for financial @entity137 ) in 2 sets of @entity5 @entity1 (pts). @entity13552 (S1): pts with Stage IV @entity5 on chemotherapy. Gradations of FTox were determined by ROC analyses based on conventions for clinically meaningful small (0.2), medium (0.5) and large (0.8) effect sizes (e.s.) for the FACT-G HRQoL instrument. Demographics, income, @entity1316 (POMS), and symptoms (EORTC QLQ-C30) were collected. We computed   (2) (Eta squared) to estimate the magnitude of the variability in HRQoL explained by specific symptoms. @entity21044 (S2): pts and survivors with @entity259 within 3 years of diagnosis. In S2, HRQoL was assessed by the thyroid-specific City of Hope HRQoL measure. RESULTS: A total of 600 @entity5 pts were assessed (233 in the S1 and 367 in the S2). S1: the median COST value was 23 (range 0-44). ROC curve analyses produced 4 COST grades (G): G0 >=  26 (99 pts, 42%); G1: >=  14-26 (71 pts, 31%); G2: > 0-14 (58 pts, 25%); and G3: = 0 (5 pts, 2%). Pts with G0 had no impact of FTox on their HRQoL. Absolute e.s. decreases in FACT-G by grade compared to G0 were: G1, 0.59 (95% CI: 0.27 - 0.90); G2, 0.92 (CI: 0.59 - 1.26); G3, 1.77 (CI: 0.83 - 2.70). In multivariate analyses, mood explained 22% (CI 13-31%) of the variability in FACT-G; FTox, 7.6% (CI 2.2-15%); fatigue, 5.6% (CI 1.1-12%); @entity158 , 3.6% (CI 0.3-9.6%); and @entity1277 , 3.4%(CI 0.3-9.3%). VS: applying the COST thresholds to S2, we had: G0: 154 pts (42%); G1: 126 (34%); G2: 84 (23%); and G3: 3(1%). The decreases in HRQoL measured in e.s. were: G1: 0.84 (CI: 0.68 - 1.00); G2: 1.88 (CI: 1.67 - 2.09); G3: 2.99 (CI: 2.29 - 3.68). The association between HRQoL and FTox was significant in multivariate models in both sets (p < 0.001). CONCLUSIONS: We developed and validated a FTox grading system in 2 different set of @entity1 . This grading was anchored on independent and clinically meaningful changes in HRQoL attributable to FTox. FTox is a meaningful event that can be objectively measured, and should be included in the assessment of @entity1 -centered outcomes.

Grading financial XXXX based upon its impact on health-related quality of life (HRQol).

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity13552 :: ('9739', 'Gene') :: ['Set 1'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer'] @entity21044 :: ('29072', 'Gene') :: ['Set 2'] @entity1316 :: ('MESH:D019964', 'Disease') :: ['mood disorders'] @entity1277 :: ('MESH:D001068', 'Disease') :: ['loss of appetite'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid cancer']
@entity137 :: (MESH:D064420,Disease) :: ['toxicity']
